Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis.
DAA therapies
HCV-related cirrhosis
chronic hepatitis C
glycated haemoglobin
type 2 diabetes mellitus
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
07
04
2021
received:
17
09
2020
accepted:
15
04
2021
pubmed:
25
4
2021
medline:
20
8
2021
entrez:
24
4
2021
Statut:
ppublish
Résumé
Data concerning the impact of hepatitis C virus (HCV) cure on type 2 diabetes mellitus (T2DM) are controversial. The aim of the study was to evaluate the effects of anti-HCV direct-acting antiviral (DAA) treatments on long-term glucose control in HCV/T2DM patients with chronic hepatitis C (CHC) or with cirrhosis. One hundred and eighty-two consecutive HCV/T2DM patients who achieved a viral clearance by DAA treatment were enrolled. Seventy or 182 of them had CHC, and 112 had cirrhosis. Clinical, biochemical and instrumental parameters were recorded at baseline and at 48, 96 and 120 weeks (48w, 96w and 120w, respectively) after stopping DAA therapy. At baseline, the overall study population had a mean of glycated haemoglobin (HbA1c) value of 7.2% (ranging from 5 to 11.2), without any significant differences between CHC and cirrhosis [7.1 and 7.2, respectively]. Evaluation over time of HbA1c variations showed a significant improvement of glucose control at all post-treatment time points compared with baseline in CHC patients (P = .001). In cirrhotic patients, a significant decrease of HbA1c levels was only found when comparing HbA1c values between baseline and 48w time-point (P = .001), whereas this improvement disappeared at both 98w and 120w (P = .8 and P = .3, respectively). Multivariate logistic regression analysis showed that patients with chronic hepatitis have a 2.5 (CI 1.066-5.945) times greater chance of achieving an improvement of glycaemic values than patients with liver cirrhosis (P = .035). DAA-based HCV cure induces a significant and persistent amelioration of glycaemic control in HCV/diabetic patients with chronic hepatitis, whereas cirrhotic HCV/diabetic subjects have only a transient benefit from the virus elimination.
Sections du résumé
BACKGROUND
Data concerning the impact of hepatitis C virus (HCV) cure on type 2 diabetes mellitus (T2DM) are controversial. The aim of the study was to evaluate the effects of anti-HCV direct-acting antiviral (DAA) treatments on long-term glucose control in HCV/T2DM patients with chronic hepatitis C (CHC) or with cirrhosis.
METHODS
One hundred and eighty-two consecutive HCV/T2DM patients who achieved a viral clearance by DAA treatment were enrolled. Seventy or 182 of them had CHC, and 112 had cirrhosis. Clinical, biochemical and instrumental parameters were recorded at baseline and at 48, 96 and 120 weeks (48w, 96w and 120w, respectively) after stopping DAA therapy.
RESULTS
At baseline, the overall study population had a mean of glycated haemoglobin (HbA1c) value of 7.2% (ranging from 5 to 11.2), without any significant differences between CHC and cirrhosis [7.1 and 7.2, respectively]. Evaluation over time of HbA1c variations showed a significant improvement of glucose control at all post-treatment time points compared with baseline in CHC patients (P = .001). In cirrhotic patients, a significant decrease of HbA1c levels was only found when comparing HbA1c values between baseline and 48w time-point (P = .001), whereas this improvement disappeared at both 98w and 120w (P = .8 and P = .3, respectively). Multivariate logistic regression analysis showed that patients with chronic hepatitis have a 2.5 (CI 1.066-5.945) times greater chance of achieving an improvement of glycaemic values than patients with liver cirrhosis (P = .035).
CONCLUSION
DAA-based HCV cure induces a significant and persistent amelioration of glycaemic control in HCV/diabetic patients with chronic hepatitis, whereas cirrhotic HCV/diabetic subjects have only a transient benefit from the virus elimination.
Identifiants
pubmed: 33894103
doi: 10.1111/liv.14905
pmc: PMC8506140
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2059-2067Informations de copyright
© 2021 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Gastroenterology. 2016 Jan;150(1):145-155.e4; quiz e15-6
pubmed: 26386298
Eur Heart J. 2020 Jan 1;41(1):12-85
pubmed: 31820000
Am J Gastroenterol. 2019 Aug;114(8):1275-1282
pubmed: 31135449
World J Gastroenterol. 2017 Mar 7;23(9):1697-1711
pubmed: 28321170
Dig Liver Dis. 2007 Aug;39(8):748-52
pubmed: 17604238
Dig Liver Dis. 2016 Feb;48(2):105-11
pubmed: 26614641
Diabetes Care. 2017 Sep;40(9):1173-1180
pubmed: 28659309
Front Endocrinol (Lausanne). 2015 Sep 14;6:134
pubmed: 26441826
Liver Int. 2019 Jun;39(6):1027-1032
pubmed: 30570808
J Gastroenterol Hepatol. 2017 Jul;32(7):1355-1362
pubmed: 27930829
Liver Int. 2016 Jul;36(7):936-48
pubmed: 26972930
J Clin Med. 2020 Feb 19;9(2):
pubmed: 32092892
Gastroenterology. 2018 Aug;155(2):411-421.e4
pubmed: 29655836
J Viral Hepat. 2020 Feb;27(2):188-194
pubmed: 31596996
Liver Int. 2021 Sep;41(9):2059-2067
pubmed: 33894103
J Viral Hepat. 2020 Mar;27(3):333-337
pubmed: 31698529
Liver Int. 2017 Jul;37(7):950-962
pubmed: 27943508
Aliment Pharmacol Ther. 2019 Jun;49(11):1442-1447
pubmed: 30932218
Pathogens. 2018 Jul 31;7(3):
pubmed: 30065220
Curr HIV/AIDS Rep. 2019 Oct;16(5):389-394
pubmed: 31482299
Hepatology. 2014 Oct;60(4):1139-49
pubmed: 24500979
J Hepatol. 2014 Nov;61(1 Suppl):S69-78
pubmed: 25443347
Liver Int. 2020 Nov;40(11):2820-2827
pubmed: 32666695
Acta Diabetol. 2016 Oct;53(5):761-7
pubmed: 27193886
J Med Virol. 2018 Feb;90(2):320-327
pubmed: 28960353
J Viral Hepat. 2012 May;19(5):341-5
pubmed: 22497813
J Clin Invest. 2017 Jan 3;127(1):83-93
pubmed: 28045401
Am J Epidemiol. 2008 Mar 15;167(6):743-50
pubmed: 18203734
J Hepatol. 2008 May;48(5):721-7
pubmed: 18308416
J Hepatol. 2015 Jul;63(1):237-64
pubmed: 25911335
World J Hepatol. 2016 Jan 18;8(2):131-8
pubmed: 26807209
AIDS Rev. 2018 Jan-Mar;20(1):58-70
pubmed: 29369303
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):679-682
pubmed: 32438332
Aliment Pharmacol Ther. 2017 Oct;46(7):688-695
pubmed: 28791711
J Hepatol. 2012;56 Suppl 1:S56-65
pubmed: 22300466